Shanghai-based Abbisko Therapeutics announces U.S. FDA acceptance of NDA for pimicotinib, its CSF-1R inhibitor for tenosynovial giant cell tumor, building on China NMPA approval and Merck KGaA global license.

Spanish pharmaceutical company ESTEVE announces acquisition of TerSera's Infusion Specialty Therapies unit, gaining US market expansion with Prialt and Quzyttir while consolidating European operations.

China-based Lynk Pharmaceuticals has announced positive Phase III topline results for its selective JAK1 inhibitor zemprocitinib in rheumatoid arthritis, strengthening its late-stage immunology pipeline and commercialization partnership with Simcere in Greater China.

The European Medicines Agency welcomes the political agreement on modernized EU pharmaceutical legislation, enhancing medicine development, authorization, supply security, and innovation through new rules on shortages and regulatory sandboxes.

SCIEX has begun localized production and support of its XR QTOF and ZenoTOF mass spectrometry systems in China, enhancing access to advanced analytical equipment for Asian biopharma R&D and QC labs.

EU institutions have reached a political agreement on a comprehensive overhaul of pharmaceutical legislation aimed at boosting innovation, speeding approvals and improving supply security across Europe, with significant regulatory and market implications for drug developers and manufacturers.

China’s biopharma industry enters 2026 with record outbound licensing value, robust Hong Kong IPO and capital-market activity, and policy moves to fast-track innovative drugs and dual insurance coverage, reshaping strategic priorities for Asian pharma executives and investors.

The European Pharmacopoeia has reached a key milestone in phasing out animal-based endotoxin testing, pushing European pharmaceutical manufacturers to adopt advanced in vitro alternatives in their quality control strategies from 2026.

Hisamitsu Pharmaceutical's founding family member and CEO Kazuhide Nakatomi is negotiating a management buyout of the Japanese firm at a $2.9 billion valuation.

Esco Aster, a Singapore-based CRDMO, has signed a clinical cGMP manufacturing contract with Shine-On Biomedical for an innovative HLA-G targeting exosome drug delivery platform.[7]